Abstract

Abstract During the COVID‐19 pandemic, non‐pharmaceutical interventions were introduced to reduce exposure to respiratory viruses. However, these measures may have led to an “immunity debt” that could make the population more vulnerable. The goal of this study was to examine the transmission dynamics of seasonal influenza in the years 2023–2024. Respiratory samples from patients with influenza‐like illness were collected and tested for influenza A and B viruses. The electronic medical records of index cases from October 2023 to March 2024 were analyzed to determine their clinical and epidemiological characteristics. A total of 48984 positive cases were detected, with a pooled prevalence of 46.9% (95% CI 46.3–47.5). This season saw bimodal peaks of influenza activity, with influenza A peaked in week 48, 2023, and influenza B peaked in week 1, 2024. The pooled positive rates were 28.6% (95% CI 55.4–59.6) and 18.3% (95% CI 18.0–18.7) for influenza A and B viruses, respectively. The median values of instantaneous reproduction number were 5.5 (IQR 3.0–6.7) and 4.6 (IQR 2.4–5.5), respectively. The hospitalization rate for influenza A virus (2.2%, 95% CI 2.0–2.5) was significantly higher than that of influenza B virus (1.1%, 95% CI 0.9–1.4). Among the 17 clinical symptoms studied, odds ratios of 15 symptoms were below 1 when comparing influenza A and B positive inpatients, with headache, weakness, and myalgia showing significant differences. This study provides an overview of influenza dynamics and clinical symptoms, highlighting the importance for individuals to receive an annual influenza vaccine.